Biosig Technologies (BSGM) Financials

BioSig Technologies (NASDAQ: STEX) shows a highly mixed but increasingly cash-rich balance sheet, alongside ongoing heavy losses and very limited operating revenue. Over the last four years, the company has repeatedly relied on financing and large non-cash items to stay afloat, while recent quarters show a dramatic jump in asset values and equity that appears driven more by financing and restructuring than by core business performance.

The biggest takeaway for retail investors: STEX currently has far more liquidity than it did a year ago, but its operating model is still not self-sustaining. Revenue remains minimal, losses remain large, and the latest quarter included a sizable operating loss despite a strong cash position.

• Liquidity improved sharply in Q1 2026. Cash and equivalents were $6.9 million and short-term investments were $23.8 million, giving the company a much stronger near-term liquidity position than in prior periods.
• Total current assets jumped to $45.9 million in Q1 2026. That is a major improvement from $15.0 million in Q3 2025 and $4.0 million in Q1 2025.
• Equity turned positive again in Q1 2026. Total equity and noncontrolling interests reached $159.2 million, reversing the negative equity seen in 2024 and Q3 2025.
• Recent financing has supported the balance sheet. The company raised $37.2 million from common equity issuance in Q1 2026, helping offset debt repayment and operating cash burn.
• Debt appears reduced at the short-term level. Short-term debt was $0 in Q1 2026, down from a period when financing activity included debt issuance and repayment.
• Operating cash burn narrowed in Q1 2026 compared with late 2025. Operating cash flow was negative $10.2 million versus negative $3.0 million in Q4 2025, but the quarter included unusual items and still reflects ongoing cash outflow.
• Non-cash add-backs remain large. Amortization of $12.0 million and other non-cash adjustments helped reduce reported cash burn, indicating earnings still depend heavily on accounting adjustments.
• Asset composition is dominated by goodwill and intangibles. In Q1 2026, goodwill was $69.8 million and intangible assets were $42.4 million, which means a large portion of assets is not hard cash or receivables.
• Core revenue is still absent. The company reported zero revenue in Q1 2026, as it did in most quarters shown.
• Losses remain substantial. Q1 2026 net loss was $46.7 million, and the company has posted repeated quarterly losses across the last four years.

Trend analysis over the last several years

STEX’s income statement shows no consistent revenue base. Most quarters reported either zero revenue or only token revenue, such as $13,000 in some 2024 quarters. Meanwhile, operating expenses have remained significant, especially SG&A, which ranged from roughly $1.1 million to more than $40 million depending on the quarter. That has produced consistent operating losses.

The cash flow statement tells a similar story. Operating cash flow has been negative in most periods, including negative $1.1 million in Q1 2025, negative $5.0 million in Q3 2025, negative $3.0 million in Q4 2025, and negative $10.2 million in Q1 2026. The company has repeatedly depended on equity issuance and other financing sources to stay liquid.

The balance sheet has changed dramatically. In early 2024, STEX had only $4.4 million in assets and $5.8 million in liabilities, with negative equity. By Q1 2026, total assets were $173.3 million and equity was positive again. However, much of that increase came from common stock, goodwill, and intangible assets rather than from organic business growth.

What investors should watch next: whether STEX can generate meaningful revenue, reduce operating losses, and stop depending on dilutive financing. Until then, the stock likely remains a high-risk turnaround/speculative situation rather than a proven operating business.